BridgeMD
New treatment option for Thyroid Cancer
Official title Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
ClinicalTrials.gov ID: NCT06787911
What this study is testing
What is Donafeib with Sintilimab?
Donafeib with Sintilimab is an investigational medicine, being studied as a potential treatment for thyroid cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant therapy receive surgical treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Voluntarily enroll and sign a written informed consent form;
- Age\>=18 years old,\<=80 years old, regardless of gender;
- Locally advanced differentiated thyroid carcinoma (DTC) diagnosed by pathological histology;
- Locally advanced DTC is defined as meeting at least one of the criteria: surgery is expected to be difficult to complete R0/R1 resection; AJCC...
- Voluntarily undergo tumor biopsy/operation at enrollment and exit.
You likely can't join if
- Other histological subtypes of thyroid cancer (such as undifferentiated carcinoma, myeloid carcinoma, lymphoma, or sarcoma) that are not associated...
- Patients who undergo thyroid cancer radical surgery again;
- Central nervous system metastasis and/or cancerous meningitis with clinical symptoms, and a history of leptomeningeal carcinoma;
- Within the first 5 years of randomization, cancer with a different primary site or histological type from thyroid cancer, or cancer coexisting with...
- Previous or current congenital or acquired immunodeficiency disease;
- Active or previously documented autoimmune disease or inflammatory disease (including but not limited to: autoimmune hepatitis, interstitial...
See the full eligibility criteria
Who can join
- Voluntarily enroll and sign a written informed consent form;
- Age\>=18 years old,\<=80 years old, regardless of gender;
- Locally advanced differentiated thyroid carcinoma (DTC) diagnosed by pathological histology;
- Locally advanced DTC is defined as meeting at least one of the criteria: surgery is expected to be difficult to complete R0/R1 resection; AJCC defined T4 stage: any size of tumor infiltrating beyond the thyroid capsule...
- Voluntarily undergo tumor biopsy/operation at enrollment and exit.
- Have not received any anti-tumor treatment in the past;
- According to the evaluation criteria for the how well it works of solid tumors (RECIST version 1.1), there should be at least one imaging measurable lesion. Lesions located within the radiation field of previous...
- The physical condition (PS) score of the Eastern Cancer Collaborative Group (ECOG) is 0-2 points;
- Expected survival time\>3 months;
- Female patients with fertility (referring to those who have not undergone menopause or surgical sterilization) must have a negative serum pregnancy test result within 7 days before the study drug administration;
- Female or male patients with fertility must take reliable contraceptive measures during the study drug use period and within 60 days after the last medication use;
- Normal function of major organs, i.e. meeting the following criteria: Blood routine examination (no blood transfusion or G-CSF used within 14 days prior to screening): a) Hemoglobin\>=90 g/L; b) Absolute neutrophil...
What rules you out
- Other histological subtypes of thyroid cancer (such as undifferentiated carcinoma, myeloid carcinoma, lymphoma, or sarcoma) that are not associated with DTC;
- Patients who undergo thyroid cancer radical surgery again;
- Central nervous system metastasis and/or cancerous meningitis with clinical symptoms, and a history of leptomeningeal carcinoma;
- Within the first 5 years of randomization, cancer with a different primary site or histological type from thyroid cancer, or cancer coexisting with thyroid cancer but with a different primary site or histological type...
- Previous or current congenital or acquired immunodeficiency disease;
- Active or previously documented autoimmune disease or inflammatory disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus...
- Have a history of severe mental illness in the past;
- Suffering from diseases that affect the absorption, distribution, metabolism, or clearance of investigational drugs (such as severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.)...
- Has undergone major surgery (as defined by the researcher) within 4 weeks prior to enrollment, or is expected to require major surgery during the study treatment period;
- Have received iodine-131 ablation or other local anti-tumor treatments within the past 3 months, or plan to undergo systemic anti-tumor treatment or external irradiation or other treatment treatments during the...
- Previously received organ or allogenic bone marrow transplantation;
- Previously received targeted therapy drugs targeting VEGF, including but not limited to anlotinib, apatinib, bevacizumab, etc;
- Previously received immune therapy drugs including but not limited to anti CTLA-4, anti PD-1, anti PD-L1, anti PD-L2, anti CD137. Therapeutic anti-tumor vaccines are not included;
- Systemic immunosuppressive drug treatment has been used within 2 weeks before enrollment, or systemic immunosuppressive drug treatment is expected to be required during the study period, except for the following cases:
- Intranasal, inhaled, topical or local injection (such as intra-articular injection) corticosteroids;
- The dose does not exceed 10 mg/day of prednisone or other equivalent systemic corticosteroids;
- Prophylactic use of corticosteroids for hypersensitivity reactions;
- Simultaneously taking drugs that may prolong QTc and/or induce apical torsion transition ventricular tachycardia (Tdp) or affect drug metabolism; Security:
- The patient has a known or suspected history of allergies to donafinib or similar drugs, or a history of hypersensitivity to chimeric or humanized antibodies or fusion proteins, or allergies to excipients of the study...
- Imaging shows that the tumor has invaded important blood vessels, or the investigator determines that the patient's tumor is highly likely to invade important blood vessels during treatment and cause fatal bleeding;
- Active bleeding or abnormal coagulation function, with a tendency to bleed or undergoing thrombolysis, anticoagulation, or antiplatelet therapy;
- Have a history of gastrointestinal bleeding within the past 4 weeks or have a clear tendency for gastrointestinal bleeding (such as known local active ulcer lesions, fecal occult blood++, if continuous fecal occult...
- Have experienced gastrointestinal perforation, abdominal fistula, or abdominal abscess within the past 6 months;
- Have experienced thrombosis or thromboembolic events within the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc;
- Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting surgery within the past 6 months...
- Active infections, including: a) AIDS virus (HIV/2 antibody) positive; b) Active hepatitis B (HBsAg positive and abnormal liver function); c) Active hepatitis C (HCV antibody positive or HCV RNA ≥ 103 copies/ml with...
- Other significant clinical and laboratory abnormalities, which the researchers believe affect the safety evaluation, such as uncontrollable diabetes, chronic kidney disease, peripheral neuropathy of grade II or above...
- Has not yet recovered from surgery, such as the presence of unhealed incisions or serious postoperative complications;
- Within 4 weeks prior to enrollment or possibly during the study period, receive any attenuated live vaccines;
- Pregnant or lactating women, as well as female or male patients with fertility who are unwilling or unable to take effective contraceptive measures; Other:
- Have a history of alcohol, psychotropic drugs, or other substance abuse within the past 6 months;
- Have received clinical trials of other drugs or medical devices within 4 weeks prior to enrollment. TSH inhibition therapy is not prohibited;
- Unable to follow the research protocol for treatment or follow up on schedule;
- Any other researcher deemed ineligible for enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.